{"id":"NCT00402779","sponsor":"M.D. Anderson Cancer Center","briefTitle":"Erlotinib Prevention of Oral Cancer (EPOC)","officialTitle":"Erlotinib Prevention of Oral Cancer (EPOC)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-11-03","primaryCompletion":"2018-06-04","completion":"2018-06-04","firstPosted":"2006-11-22","resultsPosted":"2020-04-21","lastUpdate":"2020-04-21"},"enrollment":303,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Oral Cancer"],"interventions":[{"type":"DRUG","name":"Erlotinib","otherNames":["Tarceva","OSI-774"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Erlotinib","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The goal of this clinical research study is to learn if erlotinib hydrochloride (Tarceva√¢ (OSI-774 ) can prevent cancer in the mouth of people with a high risk of developing cancer in the mouth. The safety of this drug will also be studied, as well as the drug's effect on different cells in the body.","primaryOutcome":{"measure":"Oral Cancer-free Survival in Participants Receiving Erlotinib as Compared With the Control Arm or Placebo Group.","timeFrame":"3 years","effectByArm":[{"arm":"Erlotinib","deltaMin":55,"sd":null},{"arm":"Placebo","deltaMin":18,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":4,"countries":["United States"]},"refs":{"pmids":["26540028","24320967"],"seeAlso":["http://www.mdanderson.org"]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":75},"commonTop":["Diarrhea","Rash-acneiform","Fatigue","Pruritis","Rash"]}}